Cell Biotech쎌바이오텍
049960 · KOSDAQ · ₩049960 · 쎌바이오텍
₩14,800▼ ₩30 (0.20%)End-of-day · Oct 29, 2026 · End-of-day prices.
Income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | ₩53B | ₩50B | ₩54B | ₩51B | ₩47B |
| Cost of sales | ₩15B | ₩14B | ₩15B | ₩13B | ₩11B |
| Gross profit | ₩39B | ₩36B | ₩39B | ₩38B | ₩36B |
| Operating income | ₩7.9B | ₩6.8B | ₩2.2B | ₩6.1B | ₩7.3B |
| Net income | ₩10B | ₩15B | ₩6.3B | ₩8.3B | ₩10B |
| Net income to shareholders | ₩10B | ₩15B | ₩6.3B | ₩8.3B | ₩10B |
Balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Total assets | ₩137B | ₩130B | ₩118B | ₩116B | ₩113B |
| Current assets | ₩104B | ₩97B | ₩82B | ₩76B | ₩68B |
| Cash and equivalents | ₩17B | ₩4.8B | ₩7.9B | ₩8.5B | ₩9.9B |
| Total liabilities | ₩4.9B | ₩6.2B | ₩5.8B | ₩7.7B | ₩6.2B |
| Current liabilities | ₩4.9B | ₩5.9B | ₩4.8B | ₩7.4B | ₩5.8B |
| Total equity | ₩132B | ₩124B | ₩112B | ₩108B | ₩107B |
| Shareholders' equity | ₩132B | ₩124B | ₩112B | ₩108B | ₩107B |
Cash flow
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Cash from operations | ₩11B | ₩19B | ₩7.8B | ₩13B | ₩15B |
| Capital spending | ₩3.1B | ₩1.1B | ₩1.6B | ₩2.4B | ₩849M |
| Free cash flow | ₩8B | ₩18B | ₩6.3B | ₩10B | ₩14B |
| Dividends paid | ₩3.1B | ₩3.1B | ₩3.1B | ₩3.2B | ₩3.2B |
Consolidated where available. Amounts in won.
Also known as: Cell Biotech / 쎌바이오텍 / 049960 / KRX:049960
Source: KRX statistical information